An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
Marieke A. Vollebergh(Molecular Oncology (United States)), Sabine C. Linn(Oncode Institute), Femke E. Froklage, Harm van Tinteren(Princess Máxima Center), Michael Hauptmann(Medizinische Hochschule Brandenburg Theodor Fontane), Sten Cornelissen, Elisabeth G.E. de Vries(Karolinska University Hospital), Marc J. van de Vijver(The Netherlands Cancer Institute), Esther H. Lips(Oncode Institute), Petra M. Nederlof(The Netherlands Cancer Institute), Erik H. van Beers, Lodewijk F.A. Wessels(The Netherlands Cancer Institute), Jolanda Schrama(Amsterdam Public Health), M. Holtkamp, Michiel de Bruin, Marjanka K. Schmidt(University of Cambridge), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Jelle Wesseling(Leiden University Medical Center)
Cited by 211
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k